Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company is proud to announce a travel fund for patients enrolled in a Phase II clinical study that employs their investigational LAMP-Vax™ technology to treat glioblastoma multiforme (GBM).
{iframe}https://biohive.breezio.com/article/4819366877757179364/immunomic-therapeutics-offers-travel-fund-for-clinical-trial-patients{/iframe}